{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T18:20:47Z","timestamp":1790014847977,"version":"4.0.1"},"reference-count":152,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Endocrinol"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1038\/s41574-026-01257-6","type":"journal-article","created":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T10:30:01Z","timestamp":1778495401000},"page":"477-489","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Advances in diagnosing and treating diabetic retinopathy"],"prefix":"10.1038","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8952-0659","authenticated-orcid":false,"given":"Sobha","family":"Sivaprasad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stela","family":"Vujosevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,11]]},"reference":[{"key":"1257_CR1","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1038\/s41433-024-03101-5","volume":"38","author":"Vision Loss Expert Group of the Global Burden of Disease Study & GBD 2019 Blindness and Vision Impairment Collaborators","year":"2024","unstructured":"Vision Loss Expert Group of the Global Burden of Disease Study & GBD 2019 Blindness and Vision Impairment Collaborators. Global estimates on the number of people blind or visually impaired by diabetic retinopathy: a meta-analysis from 2000 to 2020. Eye 38, 2047\u20132057 (2024).","journal-title":"Eye"},{"key":"1257_CR2","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1016\/j.ophtha.2021.04.027","volume":"128","author":"ZL Teo","year":"2021","unstructured":"Teo, Z. L. et al. Global prevalence of diabetic retinopathy and projection of burden through 2045. Ophthalmology 128, 1580\u20131591 (2021).","journal-title":"Ophthalmology"},{"key":"1257_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-024-03665-6","volume":"24","author":"M Benhamza","year":"2024","unstructured":"Benhamza, M., Dahlui, M. & Said, M. A. Determining direct, indirect healthcare and social costs for diabetic retinopathy management: a systematic review. BMC Ophthalmol. 24, 424 (2024).","journal-title":"BMC Ophthalmol."},{"key":"1257_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-025-00646-x","volume":"11","author":"S Sivaprasad","year":"2025","unstructured":"Sivaprasad, S., Wong, T. Y., Gardner, T. W., Sun, J. K. & Bressler, N. M. Diabetic retinal disease. Nat. Rev. Dis. Primers 11, 62 (2025).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"1257_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2020.100900","volume":"82","author":"J-PO Li","year":"2021","unstructured":"Li, J.-P. O. et al. Digital technology, tele-medicine and artificial intelligence in ophthalmology: a global perspective. Prog. Retin. Eye Res. 82, 100900 (2021).","journal-title":"Prog. Retin. Eye Res."},{"key":"1257_CR6","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/S0161-6420(13)38011-7","volume":"98","author":"Early Treatment Diabetic Retinopathy Study Research Group","year":"1991","unstructured":"Early Treatment Diabetic Retinopathy Study Research Group. Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Ophthalmology 98, 766\u2013785 (1991).","journal-title":"Ophthalmology"},{"key":"1257_CR7","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1016\/S0161-6420(03)00475-5","volume":"110","author":"CP Wilkinson","year":"2003","unstructured":"Wilkinson, C. P. et al. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology 110, 1677\u20131682 (2003).","journal-title":"Ophthalmology"},{"key":"1257_CR8","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/S0161-6420(13)38014-2","volume":"98","author":"Early Treatment Diabetic Retinopathy Study Research Group","year":"1991","unstructured":"Early Treatment Diabetic Retinopathy Study Research Group. Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Ophthalmology 98, 823\u2013833 (1991).","journal-title":"Ophthalmology"},{"key":"1257_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1079217","volume":"13","author":"Z Yang","year":"2022","unstructured":"Yang, Z., Tan, T. E., Shao, Y., Wong, T. Y. & Li, X. Classification of diabetic retinopathy: past, present and future. Front. Endocrinol. 13, 1079217 (2022).","journal-title":"Front. Endocrinol."},{"key":"1257_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00417-016-3548-y","volume":"255","author":"TW Gardner","year":"2017","unstructured":"Gardner, T. W. & Davila, J. R. The neurovascular unit and the pathophysiologic basis of diabetic retinopathy. Graefes Arch. Clin. Exp. Ophthalmol. 255, 1\u20136 (2017).","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"1257_CR11","doi-asserted-by":"publisher","DOI":"10.1017\/S0952523820000048","volume":"37","author":"CG Eleftheriou","year":"2020","unstructured":"Eleftheriou, C. G., Ivanova, E. & Sagdullaev, B. T. Of neurons and pericytes: the neuro-vascular approach to diabetic retinopathy. Vis. Neurosci. 37, E005 (2020).","journal-title":"Vis. Neurosci."},{"key":"1257_CR12","first-page":"299","volume":"69","author":"AE Mirescu","year":"2025","unstructured":"Mirescu, A. E. et al. Adaptive optics imaging in diabetic retinopathy: a comprehensive review. Rom. J. Ophthalmol. 69, 299\u2013309 (2025).","journal-title":"Rom. J. Ophthalmol."},{"key":"1257_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.xops.2024.100519","volume":"4","author":"AR Glassman","year":"2024","unstructured":"Glassman, A. R. et al. Visual function measurements in eyes with diabetic retinopathy: an expert opinion on available measures. Ophthalmol. Sci. 4, 100519 (2024).","journal-title":"Ophthalmol. Sci."},{"key":"1257_CR14","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/s41574-020-00451-4","volume":"17","author":"DA Antonetti","year":"2021","unstructured":"Antonetti, D. A., Silva, P. S. & Stitt, A. W. Current understanding of the molecular and cellular pathology of diabetic retinopathy. Nat. Rev. Endocrinol. 17, 195\u2013206 (2021).","journal-title":"Nat. Rev. Endocrinol."},{"key":"1257_CR15","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.ophtha.2020.10.008","volume":"128","author":"JK Sun","year":"2021","unstructured":"Sun, J. K. et al. Updating the staging system for diabetic retinal disease. Ophthalmology 128, 490\u2013493 (2021).","journal-title":"Ophthalmology"},{"key":"1257_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2022.101051","volume":"90","author":"SR Levine","year":"2022","unstructured":"Levine, S. R., Sapieha, P., Dutta, S., Sun, J. K. & Gardner, T. W. It is time for a moonshot to find \u201ccures\u201d for diabetic retinal disease. Prog. Retin. Eye Res. 90, 101051 (2022).","journal-title":"Prog. Retin. Eye Res."},{"key":"1257_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.xops.2023.100420","volume":"4","author":"R Channa","year":"2023","unstructured":"Channa, R. et al. A new approach to staging diabetic eye disease: staging of diabetic retinal neurodegeneration and diabetic macular edema. Ophthalmol. Sci. 4, 100420 (2023).","journal-title":"Ophthalmol. Sci."},{"key":"1257_CR18","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.survophthal.2024.06.006","volume":"69","author":"M Parravano","year":"2024","unstructured":"Parravano, M. et al. Multimodal imaging in diabetic retinopathy and macular edema: an update about biomarkers. Surv. Ophthalmol. 69, 893\u2013904 (2024).","journal-title":"Surv. Ophthalmol."},{"key":"1257_CR19","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/s41586-023-06555-x","volume":"622","author":"Y Zhou","year":"2023","unstructured":"Zhou, Y. et al. A foundation model for generalizable disease detection from retinal images. Nature 622, 156\u2013163 (2023).","journal-title":"Nature"},{"key":"1257_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.xops.2023.100449","volume":"4","author":"T-E Tan","year":"2024","unstructured":"Tan, T.-E. et al. Imaging modalities for assessing the vascular component of diabetic retinal disease: review and consensus for an updated staging system. Ophthalmol. Sci. 4, 100449 (2024).","journal-title":"Ophthalmol. Sci."},{"key":"1257_CR21","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1089\/tmj.2020.0008","volume":"26","author":"MD Abr\u00e0moff","year":"2020","unstructured":"Abr\u00e0moff, M. D. et al. Automated and computer-assisted detection, classification, and diagnosis of diabetic retinopathy. Telemed. J. E Health 26, 544\u2013550 (2020).","journal-title":"Telemed. J. E Health"},{"key":"1257_CR22","doi-asserted-by":"publisher","DOI":"10.1167\/tvst.14.7.11","volume":"14","author":"SR Levine","year":"2025","unstructured":"Levine, S. R. et al. Report of the 2023 Mary Tyler Moore Vision Initiative Workshop. Transl. Vis. Sci. Technol. 14, 11 (2025).","journal-title":"Transl. Vis. Sci. Technol."},{"key":"1257_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2023.101220","volume":"98","author":"SKH Szeto","year":"2024","unstructured":"Szeto, S. K. H. et al. Optical coherence tomography in the management of diabetic macular oedema. Prog. Retin. Eye Res. 98, 101220 (2024).","journal-title":"Prog. Retin. Eye Res."},{"key":"1257_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2023.101206","volume":"97","author":"NK Waheed","year":"2023","unstructured":"Waheed, N. K. et al. Optical coherence tomography angiography in diabetic retinopathy. Prog. Retin. Eye Res. 97, 101206 (2023).","journal-title":"Prog. Retin. Eye Res."},{"key":"1257_CR25","doi-asserted-by":"publisher","DOI":"10.1167\/tvst.12.7.12","volume":"12","author":"J Reche","year":"2023","unstructured":"Reche, J. et al. High-resolution optical coherence tomography in healthy individuals provides resolution at the cellular and subcellular levels. Transl. Vis. Sci. Technol. 12, 12 (2023).","journal-title":"Transl. Vis. Sci. Technol."},{"key":"1257_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2024.1473176","volume":"12","author":"X Xu","year":"2024","unstructured":"Xu, X. et al. The application of artificial intelligence in diabetic retinopathy: progress and prospects. Front. Cell Dev. Biol. 12, 1473176 (2024).","journal-title":"Front. Cell Dev. Biol."},{"key":"1257_CR27","doi-asserted-by":"publisher","first-page":"304","DOI":"10.2337\/dc23-0993","volume":"47","author":"C Lam","year":"2024","unstructured":"Lam, C. et al. Performance of artificial intelligence in detecting diabetic macular edema from fundus photography and optical coherence tomography images: a systematic review and meta-analysis. Diabetes Care 47, 304\u2013319 (2024).","journal-title":"Diabetes Care"},{"key":"1257_CR28","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.ophtha.2006.06.052","volume":"114","author":"DJ Browning","year":"2007","unstructured":"Browning, D. J. et al. Relationship between optical coherence tomography-measured central retinal thickness and visual acuity in diabetic macular edema. Ophthalmology 114, 525\u2013536 (2007).","journal-title":"Ophthalmology"},{"key":"1257_CR29","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1097\/IAE.0000000000003914","volume":"43","author":"S Vujosevic","year":"2023","unstructured":"Vujosevic, S. & Ting, D. S. Is central retina thickness the most relevant parameter in the management of diabetic macular edema? Retina 43, 1639\u20131643 (2023).","journal-title":"Retina"},{"key":"1257_CR30","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1001\/jamaophthalmol.2014.2350","volume":"132","author":"JK Sun","year":"2014","unstructured":"Sun, J. K. et al. Disorganization of the retinal inner layers as a predictor of visual acuity in eyes with center-involved diabetic macular edema. JAMA Ophthalmol. 132, 1309\u20131316 (2014).","journal-title":"JAMA Ophthalmol."},{"key":"1257_CR31","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1016\/j.oret.2024.04.005","volume":"8","author":"S Vujosevic","year":"2024","unstructured":"Vujosevic, S. et al. Severity of disorganization of retinal layers and visual function impairment in diabetic retinopathy. Ophthalmol. Retina 8, 880\u2013888 (2024).","journal-title":"Ophthalmol. Retina"},{"key":"1257_CR32","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1097\/IAE.0000000000002179","volume":"39","author":"AC Onishi","year":"2019","unstructured":"Onishi, A. C. et al. Multilevel ischemia in disorganization of the retinal inner layers on projection-resolved optical coherence tomography angiography. Retina 39, 1588\u20131594 (2019).","journal-title":"Retina"},{"key":"1257_CR33","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.oret.2022.07.010","volume":"7","author":"W-S Tsai","year":"2023","unstructured":"Tsai, W.-S. et al. Characterization of the structural and functional alteration in eyes with diabetic macular ischemia. Ophthalmol. Retina 7, 142\u2013152 (2023).","journal-title":"Ophthalmol. Retina"},{"key":"1257_CR34","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ajo.2023.09.007","volume":"257","author":"W-S Tsai","year":"2024","unstructured":"Tsai, W.-S. et al. Topographic correlation of microperimetry with structural characteristics in diabetic macular ischemia. Am. J. Ophthalmol. 257, 25\u201333 (2024).","journal-title":"Am. J. Ophthalmol."},{"key":"1257_CR35","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.ajo.2017.06.026","volume":"181","author":"S Vujosevic","year":"2017","unstructured":"Vujosevic, S. et al. Diabetic macular edema with and without subfoveal neuroretinal detachment: two different morphologic and functional entities. Am. J. Ophthalmol. 181, 149\u2013155 (2017).","journal-title":"Am. J. Ophthalmol."},{"key":"1257_CR36","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41433-022-02056-9","volume":"37","author":"S Vujosevic","year":"2023","unstructured":"Vujosevic, S. et al. Optical coherence tomography as retinal imaging biomarker of neuroinflammation\/neurodegeneration in systemic disorders in adults and children. Eye 37, 203\u2013219 (2023).","journal-title":"Eye"},{"key":"1257_CR37","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1016\/j.survophthal.2024.07.006","volume":"69","author":"S Vujosevic","year":"2024","unstructured":"Vujosevic, S. et al. Role of inflammation in diabetic macular edema and neovascular age-related macular degeneration. Surv. Ophthalmol. 69, 870\u2013881 (2024).","journal-title":"Surv. Ophthalmol."},{"key":"1257_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1055087","volume":"13","author":"T Yue","year":"2022","unstructured":"Yue, T. et al. The role of inflammation in immune system of diabetic retinopathy: molecular mechanisms, pathogenetic role and therapeutic implications. Front. Immunol. 13, 1055087 (2022).","journal-title":"Front. Immunol."},{"key":"1257_CR39","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1097\/IAE.0000000000001304","volume":"37","author":"S Vujosevic","year":"2017","unstructured":"Vujosevic, S. et al. Hyperreflective retinal spots in normal and diabetic eyes. Retina 37, 1092\u20131103 (2017).","journal-title":"Retina"},{"key":"1257_CR40","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/j.oret.2022.03.020","volume":"6","author":"H Huang","year":"2022","unstructured":"Huang, H., Jansonius, N. M., Chen, H. & Los, L. I. Hyperreflective dots on OCT as a predictor of treatment outcome in diabetic macular edema. Ophthalmol. Retina 6, 814\u2013827 (2022).","journal-title":"Ophthalmol. Retina"},{"key":"1257_CR41","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1097\/IAE.0000000000001070","volume":"36","author":"IP Chatziralli","year":"2016","unstructured":"Chatziralli, I. P., Sergentanis, T. N. & Sivaprasad, S. Hyperreflective foci as an independent visual outcome predictor in macular edema due to retinal vascular diseases treated with intravitreal dexamethasone or ranibizumab. Retina 36, 2319\u20132328 (2016).","journal-title":"Retina"},{"key":"1257_CR42","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23147585","volume":"23","author":"MR Munk","year":"2022","unstructured":"Munk, M. R. et al. The role of intravitreal corticosteroids in the treatment of DME: predictive OCT biomarkers. Int. J. Mol. Sci. 23, 7585 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"1257_CR43","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1097\/IAE.0b013e3182a48917","volume":"34","author":"S Sonoda","year":"2014","unstructured":"Sonoda, S. et al. Retinal morphologic changes and concentrations of cytokines in eyes with diabetic macular edema. Retina 34, 741\u2013748 (2014).","journal-title":"Retina"},{"key":"1257_CR44","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/aos.12812","volume":"94","author":"S Vujosevic","year":"2016","unstructured":"Vujosevic, S. et al. Proteome analysis of retinal glia cells-related inflammatory cytokines in the aqueous humour of diabetic patients. Acta Ophthalmol. 94, 56\u201364 (2016).","journal-title":"Acta Ophthalmol."},{"key":"1257_CR45","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.preteyeres.2017.07.002","volume":"60","author":"AH Kashani","year":"2017","unstructured":"Kashani, A. H. et al. Optical coherence tomography angiography: a comprehensive review of current methods and clinical applications. Prog. Retin. Eye Res. 60, 66\u2013100 (2017).","journal-title":"Prog. Retin. Eye Res."},{"key":"1257_CR46","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.66.14.45","volume":"66","author":"S Kakihara","year":"2025","unstructured":"Kakihara, S., Zhuang, K. & Fawzi, A. A. Macular deep capillary plexus ischemia as a biomarker for identifying referable diabetic retinopathy. Invest. Ophthalmol. Vis. Sci. 66, 45 (2025).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"1257_CR47","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1016\/j.oret.2022.05.028","volume":"6","author":"PL Nesper","year":"2022","unstructured":"Nesper, P. L., Ong, J. X. & Fawzi, A. A. Deep capillary geometric perfusion deficits on OCT angiography detect clinically referable eyes with diabetic retinopathy. Ophthalmol. Retina 6, 1194\u20131205 (2022).","journal-title":"Ophthalmol. Retina"},{"key":"1257_CR48","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1001\/jamaophthalmol.2023.1821","volume":"141","author":"D Yang","year":"2023","unstructured":"Yang, D. et al. Assessment of parafoveal diabetic macular ischemia on optical coherence tomography angiography images to predict diabetic retinal disease progression and visual acuity deterioration. JAMA Ophthalmol. 141, 641\u2013649 (2023).","journal-title":"JAMA Ophthalmol."},{"key":"1257_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2021.101033","volume":"89","author":"CMG Cheung","year":"2022","unstructured":"Cheung, C. M. G. et al. Diabetic macular ischaemia \u2014 a new therapeutic target? Prog. Retin. Eye Res. 89, 101033 (2022).","journal-title":"Prog. Retin. Eye Res."},{"key":"1257_CR50","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics14030326","volume":"14","author":"N Wijesingha","year":"2024","unstructured":"Wijesingha, N. et al. Optical coherence tomography angiography as a diagnostic tool for diabetic retinopathy. Diagnostics 14, 326 (2024).","journal-title":"Diagnostics"},{"key":"1257_CR51","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1038\/s41433-024-02989-3","volume":"38","author":"S Vujosevic","year":"2024","unstructured":"Vujosevic, S. et al. Macula vs periphery in diabetic retinopathy: OCT-angiography and ultrawide field fluorescein angiography imaging of retinal non perfusion. Eye 38, 1668\u20131673 (2024).","journal-title":"Eye"},{"key":"1257_CR52","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1016\/j.ophtha.2013.05.004","volume":"120","author":"PS Silva","year":"2013","unstructured":"Silva, P. S. et al. Peripheral lesions identified by mydriatic ultrawide field imaging: distribution and potential impact on diabetic retinopathy severity. Ophthalmology 120, 2587\u20132595 (2013).","journal-title":"Ophthalmology"},{"key":"1257_CR53","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1001\/jamaophthalmol.2022.3131","volume":"140","author":"DM Marcus","year":"2022","unstructured":"Marcus, D. M. et al. Association of predominantly peripheral lesions on ultra-widefield imaging and the risk of diabetic retinopathy worsening over time. JAMA Ophthalmol. 140, 946\u2013953 (2022).","journal-title":"JAMA Ophthalmol."},{"key":"1257_CR54","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1001\/jamaophthalmol.2024.2890","volume":"142","author":"LP Aiello","year":"2024","unstructured":"Aiello, L. P. et al. Ultra-widefield and Early Ttreatment Diabetic Retinopathy study 7-field grading of diabetic retinopathy. JAMA Ophthalmol. 142, 856\u2013863 (2024).","journal-title":"JAMA Ophthalmol."},{"key":"1257_CR55","first-page":"923","volume":"108","author":"M Balas","year":"2024","unstructured":"Balas, M. et al. Adaptive optics imaging in diabetic retinopathy: correlation of microscopic retinal alterations with disease severity. Br. J. Ophthalmol. 108, 923\u2013931 (2024).","journal-title":"Br. J. Ophthalmol."},{"key":"1257_CR56","volume":"61","author":"J Lammer","year":"2018","unstructured":"Lammer, J. et al. Association of microaneurysms on adaptive optics scanning laser ophthalmoscopy with surrounding neuroretinal pathology and visual function in diabetes. Invest. Ophthalmol. Vis. Sci. 61, 20 (2018).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"1257_CR57","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.oret.2023.11.013","volume":"8","author":"AE Mirescu","year":"2024","unstructured":"Mirescu, A. E. et al. Adaptive optics imaging in diabetic retinopathy. Ophthalmol. Retina 8, 456\u2013467 (2024).","journal-title":"Ophthalmol. Retina"},{"key":"1257_CR58","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/9548324","volume":"2019","author":"A Zaleska-\u017bmijewska","year":"2019","unstructured":"Zaleska-\u017bmijewska, A. et al. Adaptive optics (rtx1) high-resolution imaging of photoreceptors and retinal arteries in patients with diabetic retinopathy. J. Diabetes Res. 2019, 9548324 (2019).","journal-title":"J. Diabetes Res."},{"key":"1257_CR59","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1038\/s41433-021-01825-2","volume":"36","author":"JX Ong","year":"2022","unstructured":"Ong, J. X. & Fawzi, A. A. Perspectives on diabetic retinopathy from advanced retinal vascular imaging. Eye 36, 319\u2013327 (2022).","journal-title":"Eye"},{"key":"1257_CR60","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1136\/bjo-2022-321617","volume":"107","author":"P Viggiano","year":"2023","unstructured":"Viggiano, P. et al. In vivo assessment of associations between photoreceptor structure and macular perfusion in type 1 diabetes. Br. J. Ophthalmol. 107, 1672\u20131679 (2023).","journal-title":"Br. J. Ophthalmol."},{"key":"1257_CR61","doi-asserted-by":"publisher","first-page":"319692","DOI":"10.1155\/2015\/319692","volume":"2015","author":"N Pescosolido","year":"2015","unstructured":"Pescosolido, N., Barbato, A., Stefanucci A. & Buomprisco, G. Role of electrophysiology in the early diagnosis and follow-up of diabetic retinopathy. J. Diabetes Res. 2015, 319692 (2015).","journal-title":"J. Diabetes Res."},{"key":"1257_CR62","first-page":"3711","volume":"47","author":"MA Bearse","year":"2006","unstructured":"Bearse, M. A. et al. Multifocal electroretinography predicts onset of diabetic retinopathy. Invest. Ophthalmol. Vis. Sci. 47, 3711\u20133718 (2006).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"1257_CR63","first-page":"2249","volume":"42","author":"V Parisi","year":"2001","unstructured":"Parisi, V. et al. Pattern ERG changes in diabetic patients without retinopathy. Invest. Ophthalmol. Vis. Sci. 42, 2249\u20132253 (2001).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"1257_CR64","first-page":"1","volume":"39","author":"R Sim\u00f3","year":"2014","unstructured":"Sim\u00f3, R. et al. Neurodegeneration is an early event in diabetic retinopathy: therapeutic implications. Prog. Retin. Eye Res. 39, 1\u201316 (2014) .","journal-title":"Prog. Retin. Eye Res."},{"key":"1257_CR65","first-page":"1007","volume":"42","author":"R Sim\u00f3","year":"2019","unstructured":"Sim\u00f3, R. et al. Effects of topical somatostatin and brimonidine on retinal neurodysfunction in early diabetic retinopathy (EUROCONDOR). Diabetes Care 42, 1007\u20131015 (2019).","journal-title":"Diabetes Care"},{"key":"1257_CR66","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1007\/s00592-022-01941-9","volume":"59","author":"S Vujosevic","year":"2022","unstructured":"Vujosevic, S., Limoli, C., Luzi, L. & Nucci, P. Digital innovations for retinal care in diabetic retinopathy. Acta Diabetol. 59, 1521\u20131530 (2022).","journal-title":"Acta Diabetol."},{"key":"1257_CR67","doi-asserted-by":"publisher","first-page":"e124","DOI":"10.1016\/S2589-7500(20)30287-9","volume":"3","author":"DV Gunasekeran","year":"2021","unstructured":"Gunasekeran, D. V. et al. Digital health during COVID-19: lessons from operationalising new models of care in ophthalmology. Lancet Digit. Health 3, e124\u2013e134 (2021).","journal-title":"Lancet Digit. Health"},{"key":"1257_CR68","doi-asserted-by":"publisher","DOI":"10.1186\/s40662-024-00389-y","volume":"11","author":"J Yao","year":"2024","unstructured":"Yao, J. et al. Novel artificial intelligence algorithms for diabetic retinopathy and diabetic macular edema. Eye Vis. 11, 23 (2024).","journal-title":"Eye Vis."},{"key":"1257_CR69","doi-asserted-by":"publisher","DOI":"10.1038\/s41746-018-0040-6","volume":"1","author":"MD Abr\u00e0moff","year":"2018","unstructured":"Abr\u00e0moff, M. D. et al. Pivotal trial of an autonomous AI-based diagnostic system for detection of diabetic retinopathy in primary care offices. NPJ Digit. Med. 1, 39 (2018).","journal-title":"NPJ Digit. Med."},{"key":"1257_CR70","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1001\/jama.2017.18152","volume":"318","author":"DSW Ting","year":"2017","unstructured":"Ting, D. S. W. et al. Development and validation of a deep learning system for diabetic retinopathy and related eye diseases using retinal images from multiethnic populations with diabetes. JAMA 318, 2211\u20132223 (2017).","journal-title":"JAMA"},{"key":"1257_CR71","doi-asserted-by":"publisher","DOI":"10.1016\/j.landig.2025.100914","volume":"7","author":"AR Rudnicka","year":"2025","unstructured":"Rudnicka, A. R. et al. Automated retinal image analysis systems to triage for grading of diabetic retinopathy: a large-scale, open-label, national screening programme in England. Lancet Digit. Health 7, 100914 (2025).","journal-title":"Lancet Digit. Health"},{"key":"1257_CR72","doi-asserted-by":"publisher","first-page":"5851","DOI":"10.1364\/BOE.506467","volume":"14","author":"T Murata","year":"2023","unstructured":"Murata, T. et al. OCT-angiography based artificial intelligence-inferred fluorescein angiography for leakage detection in retina. Biomed. Opt. Express 14, 5851\u20135863 (2023).","journal-title":"Biomed. Opt. Express"},{"key":"1257_CR73","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1001\/jamaophthalmol.2023.2271","volume":"141","author":"W Paul","year":"2023","unstructured":"Paul, W. et al. Accuracy of artificial intelligence in estimating best-corrected visual acuity from fundus photographs in eyes with diabetic macular edema. JAMA Ophthalmol. 141, 677\u2013686 (2023).","journal-title":"JAMA Ophthalmol."},{"key":"1257_CR74","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/j.oret.2025.04.016","volume":"9","author":"TE Tan","year":"2025","unstructured":"Tan, T. E. et al. Detection of center-involved diabetic macular edema with visual impairment using multimodal artificial intelligence algorithms. Ophthalmol. Retina 9, 955\u2013963 (2025).","journal-title":"Ophthalmol. Retina"},{"key":"1257_CR75","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2025.1608988","volume":"13","author":"J Zhang","year":"2025","unstructured":"Zhang, J. et al. Large language models in the management of chronic ocular diseases: a scoping review. Front. Cell Dev. Biol. 13, 1608988 (2025).","journal-title":"Front. Cell Dev. Biol."},{"key":"1257_CR76","doi-asserted-by":"publisher","first-page":"2886","DOI":"10.1038\/s41591-024-03139-8","volume":"30","author":"J Li","year":"2024","unstructured":"Li, J. et al. Integrated image-based deep learning and language models for primary diabetes care. Nat. Med. 30, 2886\u20132896 (2024).","journal-title":"Nat. Med."},{"key":"1257_CR77","doi-asserted-by":"publisher","first-page":"3580","DOI":"10.1038\/s41591-025-03859-5","volume":"31","author":"YC Tham","year":"2025","unstructured":"Tham, Y. C. et al. Building the world\u2019s first truly global medical foundation model. Nat. Med. 31, 3580\u20133585 (2025).","journal-title":"Nat. Med."},{"key":"1257_CR78","first-page":"102","volume":"37","author":"S Rachapelle","year":"2013","unstructured":"Rachapelle, S. et al. Telemedicine for diabetic retinopathy screening: systematic review. Diabetes Care 37, 102\u2013112 (2013).","journal-title":"Diabetes Care"},{"key":"1257_CR79","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/s41433-020-01262-7","volume":"35","author":"R Rajalakshmi","year":"2021","unstructured":"Rajalakshmi, R. et al. Review of retinal cameras for global coverage of diabetic retinopathy screening. Eye 35, 162\u2013172 (2021).","journal-title":"Eye"},{"key":"1257_CR80","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1001\/jamaophthalmol.2019.2923","volume":"137","author":"S Natarajan","year":"2019","unstructured":"Natarajan, S. et al. Diagnostic accuracy of community-based diabetic retinopathy screening with an offline artificial intelligence system on a smartphone. JAMA Ophthalmol. 137, 1182\u20131188 (2019).","journal-title":"JAMA Ophthalmol."},{"key":"1257_CR81","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1136\/bjophthalmol-2014-305631","volume":"99","author":"L Shi","year":"2015","unstructured":"Shi, L. et al. Telemedicine for detecting diabetic retinopathy: a systematic review and meta-analysis. Br. J. Ophthalmol. 99, 823\u2013831 (2015).","journal-title":"Br. J. Ophthalmol."},{"key":"1257_CR82","first-page":"1045","volume":"124","author":"JZ Kuo","year":"2017","unstructured":"Kuo, J. Z. et al. Cost-effectiveness of teleophthalmology. Ophthalmology 124, 1045\u20131052 (2017).","journal-title":"Ophthalmology"},{"key":"1257_CR83","first-page":"1071","volume":"43","author":"S Vujosevic","year":"2020","unstructured":"Vujosevic, S. et al. Telemedicine screening in diabetic retinopathy. Diabetes Care 43, 1071\u20131077 (2020).","journal-title":"Diabetes Care"},{"key":"1257_CR84","first-page":"1471","volume":"32","author":"RL Johnston","year":"2018","unstructured":"Johnston, R. L. et al. Virtual clinics in ophthalmology. Eye 32, 1471\u20131477 (2018).","journal-title":"Eye"},{"key":"1257_CR85","first-page":"148","volume":"104","author":"L Nicholson","year":"2020","unstructured":"Nicholson, L. et al. Asynchronous virtual clinics for diabetic retinopathy. Br. J. Ophthalmol. 104, 148\u2013152 (2020).","journal-title":"Br. J. Ophthalmol."},{"key":"1257_CR86","first-page":"99","volume":"2","author":"S Keel","year":"2019","unstructured":"Keel, S. et al. AI-enabled triage in retinal disease. Nat. Digit. Med. 2, 99 (2019) .","journal-title":"Nat. Digit. Med."},{"key":"1257_CR87","first-page":"1","volume":"63","author":"FG Holz","year":"2018","unstructured":"Holz, F. G. et al. Long-acting anti-VEGF therapies. Prog. Retin. Eye Res. 63, 1\u201325 (2018) .","journal-title":"Prog. Retin. Eye Res."},{"key":"1257_CR88","first-page":"1321","volume":"35","author":"JI Lim","year":"2015","unstructured":"Lim, J. I. et al. Importance of early treatment. Retina 35, 1321\u20131329 (2015) .","journal-title":"Retina"},{"key":"1257_CR89","volume":"10","author":"G Virgili","year":"2023","unstructured":"Virgili, G., Curran, K., Lucenteforte, E., Peto, T. & Parravano, M. Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis. Cochrane Database Syst. Rev. 10, CD007419 (2023).","journal-title":"Cochrane Database Syst. Rev."},{"key":"1257_CR90","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1097\/ICU.0000000000001167","volume":"36","author":"D Kuo","year":"2025","unstructured":"Kuo, D., Pajic, M. & Hadziahmetovic, M. Ten years later: how is AI impacting retina care today? Curr. Opin. Ophthalmol. 36, 462\u2013465 (2025).","journal-title":"Curr. Opin. Ophthalmol."},{"key":"1257_CR91","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/NCT06610747 (2025)."},{"key":"1257_CR92","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1038\/s41433-020-01205-2","volume":"35","author":"BS Gerendas","year":"2021","unstructured":"Gerendas, B. S. et al. Home-based visual function testing. Eye 35, 1954\u20131962 (2021).","journal-title":"Eye"},{"key":"1257_CR93","first-page":"1646","volume":"64","author":"PA Campochiaro","year":"2015","unstructured":"Campochiaro, P. A. Molecular pathogenesis of diabetic retinopathy. Diabetes 64, 1646\u20131654 (2015).","journal-title":"Diabetes"},{"key":"1257_CR94","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0140-6736(18)31387-4","volume":"392","author":"P Mitchell","year":"2018","unstructured":"Mitchell, P. et al. Management paradigms for DMO. Lancet 392, 213\u2013225 (2018).","journal-title":"Lancet"},{"key":"1257_CR95","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1016\/S0140-6736(17)31193-5","volume":"389","author":"S Sivaprasad","year":"2017","unstructured":"Sivaprasad, S. et al. Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY): a multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial. Lancet 389, 2193\u20132203 (2017).","journal-title":"Lancet"},{"key":"1257_CR96","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1001\/jamaophthalmol.2018.3255","volume":"136","author":"JG Gross","year":"2018","unstructured":"Gross, J. G. et al. Five-year outcomes of panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial. JAMA Ophthalmol. 136, 1138\u20131148 (2018).","journal-title":"JAMA Ophthalmol."},{"key":"1257_CR97","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.ophtha.2017.12.008","volume":"125","author":"J Figueira","year":"2018","unstructured":"Figueira, J. et al. Ranibizumab plus panretinal photocoagulation versus panretinal photocoagulation alone for high-risk proliferative diabetic retinopathy (PROTEUS study). Ophthalmology 125, 691\u2013700 (2018).","journal-title":"Ophthalmology"},{"key":"1257_CR98","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1097\/IAE.0000000000002422","volume":"39","author":"S Bonnin","year":"2019","unstructured":"Bonnin, S. et al. Anti-vascular endothelial growth factor therapy can improve diabetic retinopathy score without change in retinal perfusion. Retina 39, 426\u2013434 (2019).","journal-title":"Retina"},{"key":"1257_CR99","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.oret.2024.10.007","volume":"9","author":"CC Wykoff","year":"2025","unstructured":"Wykoff, C. C. et al. Longitudinal changes in diabetic retinopathy severity: learnings from PANORAMA. Ophthalmol. Retina 9, 91\u201394 (2025).","journal-title":"Ophthalmol. Retina"},{"key":"1257_CR100","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1038\/s41433-022-02269-y","volume":"37","author":"V Chaudhary","year":"2023","unstructured":"Chaudhary, V. et al. Role of anti-vascular endothelial growth factor in the management of non-proliferative diabetic retinopathy without centre-involving diabetic macular oedema: a meta-analysis of trials. Eye 37, 1966\u20131974 (2023).","journal-title":"Eye"},{"key":"1257_CR101","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1001\/jamaophthalmol.2017.6565","volume":"136","author":"NM Bressler","year":"2018","unstructured":"Bressler, N. M. et al. Persistent macular thickening following intravitreous aflibercept, bevacizumab, or ranibizumab for central-involved diabetic macular edema with vision impairment: a secondary analysis of a randomized clinical trial. JAMA Ophthalmol. 136, 257\u2013269 (2018).","journal-title":"JAMA Ophthalmol."},{"key":"1257_CR102","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1056\/NEJMoa1414264","volume":"372","author":"JA Wells","year":"2015","unstructured":"Wells, J. A. et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N. Engl. J. Med. 372, 1193\u20131203 (2015).","journal-title":"N. Engl. J. Med."},{"key":"1257_CR103","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ajo.2023.07.012","volume":"260","author":"CC Wykoff","year":"2023","unstructured":"Wykoff, C. C. et al. KESTREL and KITE phase 3 studies: 100-week results with brolucizumab in patients with diabetic macular edema. Am. J. Ophthalmol. 260, 70\u201383 (2023).","journal-title":"Am. J. Ophthalmol."},{"key":"1257_CR104","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.ophtha.2023.12.026","volume":"131","author":"TY Wong","year":"2024","unstructured":"Wong, T. Y. et al. Faricimab treat-and-extend for diabetic macular edema: two-year results from the randomized phase 3 YOSEMITE and RHINE trials. Ophthalmology 131, 708\u2013723 (2024).","journal-title":"Ophthalmology"},{"key":"1257_CR105","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1016\/S0140-6736(23)02577-1","volume":"403","author":"DM Brown","year":"2024","unstructured":"Brown, D. M. et al. Intravitreal aflibercept 8\u2009mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2\/3 trial. Lancet 403, 1153\u20131163 (2024).","journal-title":"Lancet"},{"key":"1257_CR106","doi-asserted-by":"publisher","DOI":"10.1007\/s10792-026-04043-5","volume":"46","author":"YM Al-Shammari","year":"2026","unstructured":"Al-Shammari, Y. M. et al. Clinical efficacy and safety of anti-VEGF biosimilars compared to reference anti-VEGF agents for neovascular age-related macular degeneration: a systematic review, meta-analysis, and meta-regression. Int. Ophthalmol. 46, 168 (2026).","journal-title":"Int. Ophthalmol."},{"key":"1257_CR107","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.ophtha.2022.08.012","volume":"130","author":"N Lois","year":"2023","unstructured":"Lois, N. et al. Diabetic macular edema and diode subthreshold micropulse laser: a randomized double-masked noninferiority clinical trial. Ophthalmology 130, 14\u201327 (2023).","journal-title":"Ophthalmology"},{"key":"1257_CR108","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1016\/j.ophtha.2006.02.065","volume":"113","author":"MC Gillies","year":"2006","unstructured":"Gillies, M. C. et al. Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a randomized clinical trial. Ophthalmology 113, 1533\u20131538 (2006).","journal-title":"Ophthalmology"},{"key":"1257_CR109","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.ophtha.2010.12.033","volume":"118","author":"MJ Elman","year":"2011","unstructured":"Elman, M. J. et al. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 118, 609\u2013614 (2011).","journal-title":"Ophthalmology"},{"key":"1257_CR110","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1016\/j.ophtha.2014.04.024","volume":"121","author":"DS Boyer","year":"2014","unstructured":"Boyer, D. S. et al. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology 121, 1904\u20131914 (2014).","journal-title":"Ophthalmology"},{"key":"1257_CR111","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1016\/j.ophtha.2012.04.030","volume":"119","author":"PA Campochiaro","year":"2012","unstructured":"Campochiaro, P. A. et al. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology 119, 2125\u20132132 (2012).","journal-title":"Ophthalmology"},{"key":"1257_CR112","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1159\/000545987","volume":"248","author":"G Querques","year":"2025","unstructured":"Querques, G. et al. Safety profile of intravitreal dexamethasone implant to manage diabetic macular edema: a systematic review of real-world studies. Ophthalmologica. 248, 308\u2013325 (2025).","journal-title":"Ophthalmologica."},{"key":"1257_CR113","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1001\/archopht.1990.01070090060040","volume":"108","author":"Diabetic Retinopathy Vitrectomy Study Research Group.","year":"1990","unstructured":"Diabetic Retinopathy Vitrectomy Study Research Group. Early vitrectomy for severe vitreous hemorrhage in diabetic retinopathy. Four-year results of a randomized trial: Diabetic Retinopathy Vitrectomy Study report 5. Arch. Ophthalmol. 108, 958\u2013964 (1990).","journal-title":"Arch. Ophthalmol."},{"key":"1257_CR114","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1097\/IAE.0000000000003471","volume":"42","author":"RB Rush","year":"2022","unstructured":"Rush, R. B. et al. Vitrectomy for diabetic complications: a pooled analysis of randomized controlled trials using modern techniques and equipment. Retina 42, 1292\u20131301 (2022).","journal-title":"Retina"},{"key":"1257_CR115","volume":"14","author":"YT Chen","year":"2025","unstructured":"Chen, Y. T. et al. Updates on medical and surgical managements of diabetic retinopathy and maculopathy. Asia Pac. J. Ophthalmol. 14, 100180 (2025).","journal-title":"J. Ophthalmol."},{"key":"1257_CR116","first-page":"14","volume":"32","author":"TL Edwards","year":"2018","unstructured":"Edwards, T. L. et al. Robot-assisted vitreoretinal surgery: current concepts and future perspectives. Eye 32, 14\u201321 (2018).","journal-title":"Eye"},{"key":"1257_CR117","first-page":"689","volume":"23","author":"MB Landers","year":"2003","unstructured":"Landers, M. B. et al. The use of wide-field viewing systems in vitreoretinal surgery. Retina 23, 689\u2013693 (2003).","journal-title":"Retina"},{"key":"1257_CR118","first-page":"1661","volume":"116","author":"ME Farah","year":"2009","unstructured":"Farah, M. E. et al. Vital dyes in vitreoretinal surgery: a review. Ophthalmology 116, 1661\u20131673 (2009).","journal-title":"Ophthalmology"},{"key":"1257_CR119","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1002\/kjm2.12800","volume":"40","author":"K Chong","year":"2024","unstructured":"Chong, K., Chang, J. K. & Chuang, L.-M. Recent advances in the treatment of type 2 diabetes mellitus using new drug therapies. Kaohsiung J. Med. Sci. 40, 212\u2013220 (2024).","journal-title":"Kaohsiung J. Med. Sci."},{"key":"1257_CR120","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT03811561 (2026)."},{"key":"1257_CR121","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1111\/dom.13172","volume":"20","author":"T Vilsb\u00f8ll","year":"2018","unstructured":"Vilsb\u00f8ll, T. et al. Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy. Diabetes Obes. Metab. 20, 889\u2013897 (2018).","journal-title":"Diabetes Obes. Metab."},{"key":"1257_CR122","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10163736","volume":"10","author":"AM Dascalu","year":"2021","unstructured":"Dascalu, A. M. et al. Outcomes of diabetic retinopathy post-bariatric surgery in patients with type 2 diabetes mellitus. J. Clin. Med. 10, 3736 (2021).","journal-title":"J. Clin. Med."},{"key":"1257_CR123","doi-asserted-by":"publisher","DOI":"10.1177\/19322968251318740","author":"KE Karakus","year":"2025","unstructured":"Karakus, K. E. et al. Progression of diabetic retinopathy after initiation of automated insulin delivery system in adults with type 1 diabetes. J. Diabetes Sci. Technol. https:\/\/doi.org\/10.1177\/19322968251318740 (2025).","journal-title":"J. Diabetes Sci. Technol."},{"key":"1257_CR124","volume":"3","author":"DV Do","year":"2015","unstructured":"Do, D. V. et al. Blood pressure control for diabetic retinopathy. Cochrane Database Syst. Rev. 3, CD006127 (2015).","journal-title":"Cochrane Database Syst. Rev."},{"key":"1257_CR125","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1016\/S0140-6736(07)61607-9","volume":"370","author":"AC Keech","year":"2007","unstructured":"Keech, A. C. et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet 370, 1687\u20131697 (2007).","journal-title":"Lancet"},{"key":"1257_CR126","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1056\/NEJMc1011499","volume":"364","author":"EY Chew","year":"2011","unstructured":"Chew, E. Y. & Ambrosius, W. T. Update of the ACCORD Eye Study. N. Engl. J. Med. 364, 188\u2013189 (2011).","journal-title":"N. Engl. J. Med."},{"key":"1257_CR127","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2400179","volume":"3","author":"D Preiss","year":"2024","unstructured":"Preiss, D. et al. Effect of fenofibrate on progression of diabetic retinopathy. NEJM Evid. 3, EVIDoa2400179 (2024).","journal-title":"NEJM Evid."},{"key":"1257_CR128","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT04661358 (2025)."},{"key":"1257_CR129","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT01320345 (2026)."},{"key":"1257_CR130","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1080\/14656566.2025.2496424","volume":"26","author":"LW Rowe","year":"2025","unstructured":"Rowe, L. W., Akotoye, C., Harris, A. & Ciulla, T. A. Beyond the injection: delivery systems reshaping retinal disease management. Expert. Opin. Pharmacother. 26, 939\u2013952 (2025).","journal-title":"Expert. Opin. Pharmacother."},{"key":"1257_CR131","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1080\/14712598.2023.2247987","volume":"23","author":"A Shughoury","year":"2023","unstructured":"Shughoury, A. et al. The evolving therapeutic landscape of diabetic retinopathy. Expert. Opin. Biol. Ther. 23, 969\u2013985 (2023).","journal-title":"Expert. Opin. Biol. Ther."},{"key":"1257_CR132","first-page":"133","volume":"2","author":"C Heisel","year":"2021","unstructured":"Heisel, C. et al. APE1\/Ref-1 as a novel target for retinal diseases. J. Cell Signal. 2, 133\u2013138 (2021).","journal-title":"J. Cell Signal."},{"key":"1257_CR133","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1111\/aos.15215","volume":"101","author":"E Stefansson","year":"2023","unstructured":"Stefansson, E. et al. Topical treatment of diabetic macular edema using dexamethasone ophthalmic suspension: a randomized, double-masked, vehicle-controlled study. Acta Ophthalmol. 101, 22\u201333 (2023).","journal-title":"Acta Ophthalmol."},{"key":"1257_CR134","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0304782","volume":"19","author":"SJ Bakri","year":"2024","unstructured":"Bakri, S. J. et al. Vorolanib, sunitinib, and axitinib: a comparative study of vascular endothelial growth factor receptor inhibitors and their anti-angiogenic effects. PLoS ONE 19, e0304782 (2024).","journal-title":"PLoS ONE"},{"key":"1257_CR135","doi-asserted-by":"publisher","first-page":"2390","DOI":"10.1167\/iovs.15-18272","volume":"57","author":"A Clermont","year":"2016","unstructured":"Clermont, A. et al. Plasma kallikrein mediates vascular endothelial growth factor-induced retinal dysfunction and thickening. Invest. Ophthalmol. Vis. Sci. 57, 2390\u20132399 (2016).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"1257_CR136","doi-asserted-by":"publisher","DOI":"10.1016\/j.xops.2025.100781","volume":"5","author":"QD Nguyen","year":"2025","unstructured":"Nguyen, Q. D. et al. HORNBILL: a first-in-human phase I\/IIa study of the safety, tolerability, and early pharmacodynamics of BI 764524 for diabetic macular ischemia. Ophthalmol. Sci. 5, 100781 (2025).","journal-title":"Ophthalmol. Sci."},{"key":"1257_CR137","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1001\/jamaophthalmol.2025.0006","volume":"143","author":"AM Khanani","year":"2025","unstructured":"Khanani, A. M. et al. Continuous ranibizumab via port delivery system vs monthly ranibizumab for treatment of diabetic macular edema: the PAGODA randomized clinical trial. JAMA Ophthalmol. 143, 326\u2013335 (2025).","journal-title":"JAMA Ophthalmol."},{"key":"1257_CR138","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14093205","volume":"14","author":"M Odio-Herrera","year":"2025","unstructured":"Odio-Herrera, M., Orozco-Loaiza, G. & Wu, L. Gene therapy in diabetic retinopathy and diabetic macular edema: an update. J. Clin. Med. 14, 3205 (2025).","journal-title":"J. Clin. Med."},{"key":"1257_CR139","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1001\/jamaophthalmol.2021.6331","volume":"140","author":"JK Sun","year":"2022","unstructured":"Sun, J. K., Glassman, A. R. & Jampol, L. M. Spotlight on the DRCR Retina Network\u2019s photobiomodulation for diabetic macular edema trial. JAMA Ophthalmol. 140, 304\u2013306 (2022).","journal-title":"JAMA Ophthalmol."},{"key":"1257_CR140","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/S2213-8587(18)30036-6","volume":"6","author":"S Sivaprasad","year":"2018","unstructured":"Sivaprasad, S. et al. Clinical efficacy and safety of a light mask for prevention of dark adaptation in treating and preventing progression of early diabetic macular oedema at 24 months (CLEOPATRA): a multicentre, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol. 6, 382\u2013391 (2018).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"1257_CR141","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2400009","volume":"4","author":"S Klier","year":"2025","unstructured":"Klier, S. et al. Safety and efficacy of senolytic UBX1325 in diabetic macular edema. NEJM Evid. 4, EVIDoa2400009 (2025).","journal-title":"NEJM Evid."},{"key":"1257_CR142","doi-asserted-by":"publisher","DOI":"10.1167\/tvst.13.12.32","volume":"13","author":"DS Boyer","year":"2024","unstructured":"Boyer, D. S. et al. Phase 1b dose escalation study of sozinibercept inhibition of vascular endothelial growth factors C and D with aflibercept for diabetic macular edema. Transl. Vis. Sci. Technol. 13, 32 (2024).","journal-title":"Transl. Vis. Sci. Technol."},{"key":"1257_CR143","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.21873\/invivo.13611","volume":"38","author":"KI Jung","year":"2024","unstructured":"Jung, K. I. et al. Exploring neuroprotective effects of topical brimonidine in experimental diabetic retinopathy. Vivo 38, 1609\u20131620 (2024).","journal-title":"Vivo"},{"key":"1257_CR144","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24065072","volume":"24","author":"C Garc\u00eda-L\u00f3pez","year":"2023","unstructured":"Garc\u00eda-L\u00f3pez, C. et al. The role of citicoline and coenzyme Q10 in retinal pathology. Int. J. Mol. Sci. 24, 5072 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"1257_CR145","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.564077","volume":"11","author":"UM Kinuthia","year":"2020","unstructured":"Kinuthia, U. M., Wolf, A. & Langmann, T. Microglia and inflammatory responses in diabetic retinopathy. Front. Immunol. 11, 564077 (2020).","journal-title":"Front. Immunol."},{"key":"1257_CR146","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1007\/s00109-016-1433-0","volume":"94","author":"E Beli","year":"2016","unstructured":"Beli, E. et al. CX3CR1 deficiency accelerates the development of retinopathy in a rodent model of type 1 diabetes. J. Mol. Med. 94, 1255\u20131265 (2016).","journal-title":"J. Mol. Med."},{"key":"1257_CR147","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1111\/bph.70007","volume":"182","author":"CBM Platania","year":"2025","unstructured":"Platania, C. B. M. et al. Blockade of P2X7 receptors preserves blood retinal barrier integrity by modulating the plasmalemma vesicle-associated protein: implications for diabetic retinopathy. Br. J. Pharmacol. 182, 2603\u20132620 (2025).","journal-title":"Br. J. Pharmacol."},{"key":"1257_CR148","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2024.116039","volume":"221","author":"Q Tang","year":"2024","unstructured":"Tang, Q. et al. FGF1\u0394HBS ameliorates retinal inflammation via suppressing TSPO signal in a type 2 diabetes mouse model. Biochem. Pharmacol. 221, 116039 (2024).","journal-title":"Biochem. Pharmacol."},{"key":"1257_CR149","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-21198-z","volume":"8","author":"SS Chaurasia","year":"2018","unstructured":"Chaurasia, S. S. et al. The NLRP3 inflammasome may contribute to pathologic neovascularization in the advanced stages of diabetic retinopathy. Sci. Rep. 8, 2847 (2018).","journal-title":"Sci. Rep."},{"key":"1257_CR150","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1097\/IAE.0b013e3181eac7a6","volume":"31","author":"L Wu","year":"2011","unstructured":"Wu, L. et al. Intravitreal tumor necrosis factor inhibitors in the treatment of refractory diabetic macular edema: a pilot study from the pan-American Collaborative Retina Study Group. Retina 31, 298\u2013303 (2011).","journal-title":"Retina"},{"key":"1257_CR151","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1016\/j.bbrc.2018.07.041","volume":"503","author":"YS Kim","year":"2018","unstructured":"Kim, Y. S. et al. Alpha-lipoic acid reduces retinal cell death in diabetic mice. Biochem. Biophys. Res. Commun. 503, 1307\u20131314 (2018).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"1257_CR152","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12040747","volume":"12","author":"AI D\u0103nil\u0103","year":"2024","unstructured":"D\u0103nil\u0103, A. I. et al. Aldose reductase as a key target in the prevention and treatment of diabetic retinopathy: a comprehensive review. Biomedicines 12, 747 (2024).","journal-title":"Biomedicines"}],"container-title":["Nature Reviews Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41574-026-01257-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41574-026-01257-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41574-026-01257-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T12:00:55Z","timestamp":1784030455000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41574-026-01257-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,11]]},"references-count":152,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["1257"],"URL":"https:\/\/doi.org\/10.1038\/s41574-026-01257-6","relation":{},"ISSN":["1759-5029","1759-5037"],"issn-type":[{"value":"1759-5029","type":"print"},{"value":"1759-5037","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,11]]},"assertion":[{"value":"23 April 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.S. is a consultant for AbbVie Pte Ltd, Amgen, Adverum, Apellis, Bayer, Biogen, Boehringer-Ingelheim, Novartis, Eyebiotech, Eyepoint Pharmaceuticals, Janssen Pharmaceuticals, Ocular Therapeutix, Kriya Therapeutics, OcuTerra, Roche, Stealth Biotherapeutics and Sanofi; has received research support from Boehringer Ingleheim, Roche, Optos and Bayer; and is a Trial Steering Committee member for Novo Nordisk. S.V. is a consultant for AbbVie, Adverum, Alimera, Annexon, Apellis, Bayer, Boehringer-Ingelheim, Novartis, Roche and Zeiss.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}